Home Tools
Log in
Cart

JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T2035 WHI-P258 21561-09-1 99.59%
WHI-P258
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK-binding negative control in the development of new...
T14331 Gusacitinib 1425381-60-7 99.58%
Gusacitinib
Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).
T12549 JAK-IN-11 916742-11-5 99.57%
JAK-IN-11
JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
T12266L2 Ilginatinib hydrochloride 1239358-85-0 99.55%
Ilginatinib hydrochloride
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.
T6156 Ruxolitinib (S enantiomer) 941685-37-6 99.5%
Ruxolitinib (S enantiomer)
Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
T12266 Ilginatinib 1239358-86-1 99.43%
Ilginatinib
Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.
T22416 RO495 1258296-60-4 99.4%
RO495
RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays
T2600 AG490 133550-30-8 99.39%
AG490
AG490 (Tyrphostin B42) is an inhibitor of EGFR (IC50: 0.1 μM). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn, Lck, ...
T8742 G5-7 939681-36-4 99.37%
G5-7
JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068)...
T4210 SAR-20347 1450881-55-6 99.35%
SAR-20347
SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).
T4209 TAK-659 hydrochloride 1952251-28-3 99.28%
TAK-659 hydrochloride
TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most ot...
T6104 Cerdulatinib hydrochloride 1369761-01-2 99.23%
Cerdulatinib hydrochloride
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
T3072 XL019 945755-56-6 99.23%
XL019
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.
T6920 ON123300 1357470-29-1 99.22%
ON123300
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T3076 GLPG0634 analog 1206101-20-3 99.22%
GLPG0634 analog
GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.
T78607 JAK-STAT-IN-1 1236666-76-4 99.21%
JAK-STAT-IN-1
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
T1985 WHI-P154 211555-04-3 99.19%
WHI-P154
WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.
T6914 Oclacitinib maleate 1640292-55-2 99.17%
Oclacitinib maleate
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ra...
T21503 (E/Z)-Zotiraciclib 937270-47-8 99.12%
(E/Z)-Zotiraciclib
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
T9195 SHR0302 1445987-21-2 99.11%
SHR0302
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
WHI-P258
T2035
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK-binding negative control in the development of new...
Gusacitinib
T14331
Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).
JAK-IN-11
T12549
JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
Ilginatinib hydrochloride
T12266L2
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.
Ruxolitinib (S enantiomer)
T6156
Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
Ilginatinib
T12266
Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.
RO495
T22416
RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays
AG490
T2600
AG490 (Tyrphostin B42) is an inhibitor of EGFR (IC50: 0.1 μM). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn, Lck, ...
G5-7
T8742
JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068)...
SAR-20347
T4210
SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).
TAK-659 hydrochloride
T4209
TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most ot...
Cerdulatinib hydrochloride
T6104
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
XL019
T3072
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.
ON123300
T6920
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
GLPG0634 analog
T3076
GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.
JAK-STAT-IN-1
T78607
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
WHI-P154
T1985
WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.
Oclacitinib maleate
T6914
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ra...
(E/Z)-Zotiraciclib
T21503
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
SHR0302
T9195
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
1 2 3 4 5 6 7 8 9
TargetMol